National Health Commission of the People's Republic of China

The National Health Commission of the People's Republic of China is the government body responsible for national health policy and the administration of China's healthcare system. As of August 2024, it was actively steering the rollout of the "Sanming model" of healthcare reform, with plans to promote this experience across all provinces within five years, selecting two to three key regions annually for implementation . The commission also appeared alongside two other ministries in a September 2024 joint notice allowing expanded foreign investment in medical services—including human stem cell, gene diagnosis and treatment technology development, and wholly foreign-owned hospitals in pilot cities .

In the broader architecture of Chinese healthcare, the commission sits alongside the medical products and medical insurance regulators as one of the key "three medical" pillars (医药、医疗、医保) that together form the country's healthcare system . Its policy direction in 2024 signaled both tightening control—through the Sanming reform's cost-containment mechanisms—and selective opening to foreign capital in advanced medical technologies .